The First Circuit today affirmed dismissal of a securities fraud class action against Biogen and several of its top insiders. The reason? The plaintiffs didn’t plead the scienter element in a way that satisfied the tough "strong inference" test of Tellabs, Inc. v. Makor Issues & Rights, Ltd., 127 S. Ct. 2499 (2007), under the Private Securities Litigation Reform Act. New Jersey Carpenters Pension & Annuity Funds v. Biogen IDEC Inc., No. 07-2626 (1st Cir. Aug. 7, 2008).
The world has three kinds of people: those who can count, and those who can’t.